The role of neoadjuvant chemotherapy for squamous cell cervical cancer (lb-Illb): a long-term randomized trial

Objective: to verify whether a regimen of preventive chemotherapy in the treatment of cervical carcinoma allows surgical treatment in a larger number of patients and whether cases treated with this combined neoadjuvant polychemotherapy/surgery regimen improves overall and disease-free survival rates.

Design: prospective randomized clinical study.

Setting: Department of Gynaecology and Obstetrics, University of Rome "La Sapienza".

Methods: 192 patients suffering from squamous cell carcinoma of the uterine cervix in Stages Ib-IIb were randomized to one of the following treatments: three courses of neoadjuvant chemotherapy with cisplatin, vincristine, bleomycin (NACT arm; n = 106); conventional surgery or radiotherapy alone (CO arm; n = 86). One hundred and fifty-six patients in Stage Ib-IIb (n = 86, NACT arm and n = 70, CO arm) and 16 patients in Stage III (NACT arm) who proved to be sensitive to the neoadjuvant chemotherapy, underwent radical hysterectomy. Four Stage III patients not sensitive to chemotherapy and 16 patients, Stage III, of the CO arm underwent radiotherapy.

Results: the 5-year overall survival rates for the NACT and CO arm, respectively, were 78.6% and 73.2% in Stages Ib-IIa (p = NS), 68.7% and 64.3% in Stage IIb (p = NS). A 5-year disease-free survival rate for the NACT arm and CO arm, respectively, of 77.1% and 64.3% in Stages Ib-IIa (p < .05), 56.2% and 57.1% in Stage IIb (p = NS) was found.

Conclusions: the responsiveness of cervical cancer to neoadjuvant chemotherapy allows surgical treatment in a larger number of patients and results in longer overall and disease-free survival.

Cervical cancer; Neoadjuvant chemotherapy; Radical hysterectomy

[1] Burghardt E.: "Prognostic factors and operative treatment of stages lb to IIb cervical cancer". Am. J. Obst. and Gyn., 1987, 15, 988.

[2] Piver M. S., Chung W. S.: "Prognostic significance of cervical lesion size and pelvic node metastases in cervical carcinoma". Ohstet. Gynecol., 1986, 46, 57.

[3] Burke T. W., Hoskins W. J., Heller P. B., Bibro M. C., Weiser E B., Park R. C.: "Prognostic factors associated with radical hysterectomy failure". Gynecol. Oncol., 1987, 26, 153.

[4] Sardi J. E., Di Paola G. R., Cachau A., Ortiz 0. C., Sananes C., Giaroli A. et al.: "A possibile trend in the management of the carcinoma of the cervix uteri". Gynecol. Oneal., 1986, 25, 139.

[5] Coleman R. E., Clarke J. M., Slevin M. L., Sweetenham J., WilIiams C. J., Blake P. et al.: "A phase II study of ifosfamide and cisplatino chemotherapy for metastatic or relapsed carcinoma of cervix". Cancer Chemother. Pharmacol., 1990, 27, 52.

[6] Sardi J., Sananes C., Giaroli A., Di Paola G., Maya G.: "Neoadiuvant chemotherapy in locally advanced carcinoma of the cervix uteri". Gynecol. Oneal., 1990, 38, 486.

[7] Petterson F.: "Annual report of the results of treatment m gynaeco logical cancer". Int. J. Obstet. Gynecol., 1991, 36, 27.

[8] Petterson F.: "Annual report of the results of treatment m gynaecological cancer". Stockholm: Radiumhemmet, 1988, 20.

[9] World Health Organization. "WHO Handbook for reportrng results of cancer treatment, offset publication". Geneva, WHO, 1979, 48, 16.

[10] Piver M. S., Rutledge F., Smith J. P.: "Five classes of extended hysterectomy for women with cervical cancer". Obstet. Gynecol., 1974, 44, 265.

[11] Valle G.: "Malignant tumors of the uterus: uterine cervix and body". Minerva Med., 1969, 60, 3253.

[12] Napolitano C., Tocci B., Crosara B., Mogini C., Buzzi M., Marziani R. et al.: "Management of invasive cervical carcinoma: our experience from 1961 to 1979". New Trends in Gynaec. Obstet., 1986, 2, 139.

[13] I nternational Commission on Radiation Units and Measurement "Dose and Volume Specification for Reporting lntracavitary Therapy in Gynecology". Bethesda, MD, ICRU Report 38, 1985, 1, 23.

[14] Cox D. R.: "Regression models and life tables". J. Stat. Soc. B., 1972, 33, 187.

[15] Kaplan E. L., Meier P.: "Non parametric estimation for incomplete observations". J. Am. Stat. Ass., 1958, 53, 457.

[16] Coldman A., Elwood J.: "Examining survival data". C.M.A.J., 1979, 121, 1065.

[17] Sardi J., Giaroli A., Sananes C., F erriera M., Sederini A., Berrnudez A. et al.: "Long-term follow- up of the first randomized trial using neoadiuvant chemotherapy in stage lb squamous carcinoma of the cervix: The final results". Gynecol. Oneal., 1997, 67, 61.

[18] Landoni F., Maneo A., Colombo A., Placa A., Dilani R., Perego P., Mangioni C.: "Randomised study of radical surgery versus radiotherapy for stage lb-Ila cervical cancer". Lancet, 1997, 350, 535.

[19] Fuller A. F., Elliot N., Kosloff C., Lewis J. L.: "Lymph node metastases from carcinoma of the cervix stage lb and Ila. Implication for prognosis and treatment". Gynecol. Oneal., 1982, 13, 165.

[20] Hogan W. M.: "Littman P., Griner L Miller C. L., Mikuta J. J.: "Results of radiation therapy given after radical hysterectomy". Cancer, 1982, 49, 78.

[21] Kinney W., Alvarez R. D., Reid C. G., Schray M. F., Soong S., Morley GW. et al.: "Value of adjuvant whole pelvis irradiation after Wertheim hysterectomy for early-stage squamous carcinoma of the cervix with pelvic nodal metastasis: A matched-control study". Gynecol. Oneal., 1989, 34, 258.

[22] Bolis G., Van Zainten-Przybysz I., Scarfone G., Zanaboni F., Scartabelli C., Tateo S. et al.: "Determinants of response to a cisplatin- based regimen as neoadiuvant chemiotherapy in stage Ib-Ilb invasive cervical cancer". Gynecol. Oneal., 1996, 63, 62.

[23] Dottino P. R., Plaxe S. C., Beddoe A. M., Jhonson C., Cohen C J.: "Induction cherniotherapy followed by radical surgery in cervical cancer". Gynecol. Oneal., 1991, 40, 7.

[24] Mancuso S., Benedetti Panici P., Greggi S., Scambia G.: "Neoadiuvant chemotherapy in locally advanced cervical cancer". Contrib. Gynecol. Obstet., 1989, 17, 111.

[25] Kirn D. S.,M oon H.,H wang Y. Y.,C ho S. R.: "Two-year survival: preoperative adiuvant chemotherapy in the treatment of cervical cancer stage lb and II with bulky tumor". Gynecol. Oneal., 1989, 33, 225.

[26] Lovecchio J. L., Averette H. E., Donato D., Bell J.: "5- year survival of patients with periaortic nodal metastases in clinical stage lb and Ila cervical carcinoma''. Gynecol. Oneal., 1989, 34, 43.

[27] Morrow P.: "Panel report: is pelvic irradiation beneficial in the postoperative management of stage lb squamous cell carcinoma of the cervix with pelvic node metastases treated by radical hysterectomy and pelvic lymphadenectomy?". Gynecol. Oneal., 1980, 10, 105.

[28] Tattersall M., Ramirez C., Coppleson M.: "A randomised trial of adjuvant chemotherapy after radical hysterectomy in stage lb-Ila cervical cancer patients with pelvic lymph node metastasis". Gynecol. Oneal., 1992, 46, 176.

[29] Sanases C., Giaroli A., Soderini A., Guardado N., Snaidas L., Bermudez A., Ferreira M., Di Paola G., Sardi J.: "Neoadjuvant chemotherapy followed by radical hysterectomy and postoperative adjuvant chemotherapy in the treatment of carcinoma of the cervix uteri: long term follow-up of a pilot study". Eur. J. Gynaec. Oneal., 1998, 4, 368.

[30] Valle G.: "Principles govemino the treatment of cervical carcinoma in the Clinic of Bari (1961-1967)". Minerva Ginecol., 1968, 20, 168.

[31] Burghardt E.: "Cervical cancer: results". In: Surgical Gynecologic Oncology, (eds.), Stuttgart, 1993, 302.

[32] Averette H. E., Donato D. M., Lovecchio J. L., Sevin B. U.: "Staging laparotomy and lymphadenectomy in gynecologic cancer". In: Female Genital Cancer, (eds.), New York, 1988, 659.

[33] Van Nagell J. R., Donaldson E. S., Wood E. G.: "The significance of vascular invasion and lymphocystic infiltration invasive cervical cancer". Cancer, 1978, 4, 228.

[34] McGuire W. P., Blessing J. A., Moore D., Lent S., Phopulos G.: "Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group Study". J. Clin. Oneal., 1996, 14, 792.

[35] Kudelka A. P., Winn R., Edwards C. L., Downey G., Greenberg H., Dakhil S. R. et al.: "An update of a phasell study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix". Anticancer Drugs, 1997, 8, 657.

[36] Thigpen T., Vance R., Khansur T., Malamud F.:''The role of paclitaxel in the management of patients with carcinoma of the cervix". Semin. Oncol., 1997, 24, 41.